A Primer on Chimeric Antigen Receptor T-cell Therapy-related Toxicities for the Intensivist
Journal of Intensive Care Medicine · 2024
DOI: 10.1177/08850666231205264 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Intensive Care Medicine, 2024. Verfasst von Shin Yeu Ong und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Cytokine Release Syndrome, Receptors, Chimeric Antigen, Neurotoxicity Syndromes. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 72 Literaturangaben.
Abstract (Originalsprache)
Chimeric antigen receptor (CAR) T-cell therapy is an innovative treatment approach that has shown remarkable efficacy against several hematologic malignancies. However, its use can be associated with unique and sometimes severe toxicities that require admission to intensive care unit in 30% of patients, and intensivists should be aware of immune-mediated toxicities of CAR T-cell therapy and management of adverse events. We will review available literature on current diagnostic criteria and therapeutic strategies for mitigating these most common toxicities associated with CAR T-cell therapy including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in the post-infusion period. The authors will also review other toxicities associated with CAR T-cell therapy including cytopenias, acquired immunocompromised states, and infections, and discuss the available literature on best supportive care and prophylaxis recommendations. Critical care medicine specialists play a crucial role in the management of patients undergoing CAR T-cell therapies. With the expanding use of these products in increasing numbers of treating centers, intensivists’ roles as part of the multidisciplinary team caring for these patients will have an outsized impact on the continued success of these promising therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA.
- Department of Haematology, Singapore General Hospital, Singapore, Singapore.
ORCID-Profile: John H Baird
Zitieren
APA
Ong, S. Y., & Baird, J. H. (2024). A Primer on Chimeric Antigen Receptor T-cell Therapy-related Toxicities for the Intensivist. Journal of Intensive Care Medicine. https://doi.org/10.1177/08850666231205264
Vancouver
Ong SY, Baird JH. A Primer on Chimeric Antigen Receptor T-cell Therapy-related Toxicities for the Intensivist. Journal of Intensive Care Medicine. 2024. doi:10.1177/08850666231205264
BibTeX
@article{Ong2024,
author = {Ong, Shin Yeu and Baird, John H},
title = {A Primer on Chimeric Antigen Receptor T-cell Therapy-related Toxicities for the Intensivist},
journal = {Journal of Intensive Care Medicine},
year = {2024},
doi = {10.1177/08850666231205264}
}
EUVIMED